Just a moment, the page is loading...
The Supported Studies Programme

For the latest updates on GSK’s response to COVID-19, please click here.



[Chronic Hepatitis B (CHB) Supported Studies Committee. Last updated in June 2023.]
•   Understanding the patient perspective on unmet need in CHB
•   Understanding subpopulations in CHB with greatest need for improved outcomes e.g. those at most risk from HCC
•   Understanding impact of reduced access to care on outcomes in underserved populations with CHB
•   Understanding low diagnosis rates in CHB, impact to outcomes and opportunities to improve
•   Understanding the impact of CHB on patient-important outcomes, including functional cure
•   Measuring value of functional cure versus viral suppression in CHB
•   Understanding the biological mechanisms that lead to functional cure, including heterogeneity of virological and immunological effects
•   Societal and cultural impacts on treatment decision making
•   HBsAg qualitative versus quantitative assessment in CHB – role in improving CHB management and outcomes

[Primary Biliary Cholangitis (PBC) Supported Studies Committee. Last updated in June 2023.]
• Implementing/assessing care pathways that deploy quality-of-life measures and/or symptom assessments into routine clinical care of patients with PBC
• Investigating the mechanism of disease of cholestatic pruritus: basic and clinical research into the interplay of biomarkers, for example bile acids and LPA/autotaxin
• Improving the capture of patient reported outcomes in national/international PBC registries, to increase the understanding of the severity, and quality of life impact, of symptoms of PBC

[Nucala ISS/SCS Committee. Last updated in June 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas:
• Severe eosinophilic asthma (SEA)
• Hypereosinophilic syndrome (HES)
Applications are invited in the following areas:
• Impact of mepolizumab on prevention of organ damage and disease progression
• Composite outcomes with real-world use of mepolizumab, such as remission
• Patient identification biomarkers of those at risk of worse long-term clinical outcomes
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• CNS assessment of mechanisms of mepolizumab in promoting “well-being”

[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.

© 2001-2023 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.